| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-09 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-07 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-06 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-06 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.14 | 7e-06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.14 | 2e-05 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.13 | 3e-05 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |